Enhancing Immunogenicity of Cancer Vaccines: QS-21 as an Immune Adjuvant

Publisher： Bentham Science Publishers

E-ISSN： 2212-3903|6|3|207-212

ISSN： 1574-8855

Source： Current Drug Therapy, Vol.6, Iss.3, 2011-08, pp. : 207-212

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in Predicting and Manipulating the Immunogenicity of Biotherapeutics and Vaccines

By Flower Darren R.  

BioDrugs, Vol. 23, Iss. 4, 2009-08 ,pp. : 231-240

Adis International

Access to resources Recommend Favorite

Prostate Cancer Vaccines: Current Status and Future Potential

By Doehn Christian   Böhmer Torsten   Kausch Ingo   Sommerauer Martin   Jocham Dieter  

BioDrugs, Vol. 22, Iss. 2, 2008-01 ,pp. : 71-84

Adis International

Access to resources Recommend Favorite

Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?

By  

Current Drug Therapy, Vol. 9, Iss. 3, 2014-09 ,pp. : 130-158

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic Breast Cancer Vaccines: A New Strategy for Early-Stage Disease

By Shumway Nathan M.  

BioDrugs, Vol. 23, Iss. 5, 2009-10 ,pp. : 277-287

Adis International

Access to resources Recommend Favorite

Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer†

By Garnock-Jones Karly P.   Keating Gillian M.   Scott Lesley J.  

BioDrugs, Vol. 24, Iss. 3, 2010-06 ,pp. : 207-209

Adis International

Access to resources Recommend Favorite